Dieter Hoelzer, MD, PhD from the Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany talks about aiming higher in the treatment of adult acute lymphoblastic leukemia (ALL) patients at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain. Prof. Hoelzer shares encouraging results of a 90% complete remission rate after induction therapy with the next step being to achieve the same results with less toxicity. Asparaginase, a therapy proven to be successful in children is his main focus. He discusses the aim of treatment, molecular remission and minimal residual disease (MRD) status which is important for determining outcome and future therapy.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates